According to the World Health Organization’s 2021 glioma classification protocol, which emphasizes the significance of IDH1 mutations in its hierarchical categorization and integrates histopathological features, including microvascular proliferation and/or necrosis, these patients are classified as ‘Astrocytoma, IDH-mutant, CNS WHO Grade 4’ [14]. This evidence concerns the gene IDH1 and central nervous system cancer.